The Different Impact of ERK Inhibition on Neuroblastoma, Astrocytoma, and Rhabdomyosarcoma Cell Differentiation

T D Lebedev1, E R Vagapova1, V S Prassolov1

  • 1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.

Acta Naturae
|February 7, 2022
PubMed

Insights

Aberrant ERK activity impairs cell differentiation. Suppressing ERK in TE-671 rhabdomyosarcoma cells altered morphology and myogenic gene expression, suggesting ERK

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Aberrant ERK (extracellular signal-regulated kinase) activity is linked to uncontrolled cell proliferation and malignant transformation.
  • Impaired cell differentiation is a hallmark of cancer development.
  • Understanding the role of ERK in differentiation is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the relationship between ERK tyrosine kinase activity and differentiation features in neuroblastoma, astrocytoma, and rhabdomyosarcoma cell lines.
  • To determine if ERK inhibition or induction affects cell morphology and gene expression related to differentiation.
  • To explore the impact of ERK modulation on growth factor sensitivity in cancer cells.

Main Methods:

  • Utilized a reporter system for real-time, single-cell measurement of ERK activity.
  • Employed selective ERK inhibitors to suppress ERK activity.
  • Analyzed changes in cell morphology and the expression of specific differentiation marker genes (PROM1, MYOG, PAX7).
  • Assessed the impact of ERK inhibition on cellular responses to growth factors (EGF, IGF-1, NGF, BDNF).

Main Results:

  • Suppression of ERK activity significantly altered TE-671 rhabdomyosarcoma cell morphology and expression of myogenic differentiation markers.
  • A direct correlation was observed between ERK activity levels and morphological changes at the single-cell level.
  • SH-SY5Y neuroblastoma cell differentiation induced by retinoic acid was found to be independent of ERK activity.
  • ERK inhibition enhanced TE-671 cell sensitivity to EGF, IGF-1, and NGF, and to BDNF via increased TrkB receptor expression.

Conclusions:

  • ERK activity plays a significant role in regulating differentiation in specific cancer cell types, such as rhabdomyosarcoma.
  • ERK inhibition can induce differentiation-like changes and modulate growth factor responses in certain cancer cells.
  • ERK-independent pathways are involved in the differentiation of other cancer cell types, like neuroblastoma.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
80.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K